-
Psychedelics rejected, Captagon factories and "pink cocaine": The drugs that defined 2024
21 Dec 2024 16:31 GMT
In the U.S., about half of the population takes a prescription drug every day, and half of adults have tried illicit drugs at least once. Drug use is a routine part of life for most Americans, whether it's coffee in the morning, alcoholic drinks at …
-
Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial
20 Dec 2024 20:25 GMT
(MENAFN- News Direct) --News Direct--
By Meg Flippin, Benzinga
Cognition Therapeutics Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders including dementia with Lewy bodies (DLB), announced positive …
-
Early Research Points to Possible New Parkinson's Drug
19 Dec 2024 11:40 GMT
Key Takeaways
Parkinson's patients are in dire need of new treatments
Researchers say a protein called PNA5 appears to shield the brain cells of mice from Parkinson's disease inflammation
It's still early days for this research, but PNA5 might …
-
Prasinezumab Falls Short of Statistical Significance in Primary Endpoint of PADOVA Trial for Parkinson Disease
20 Dec 2024 16:53 GMT
The investigational monoclonal antibody prasinezumab (Roche; Prothena) fell short of achieving statistical significance for the primary endpoint of time to confirmed motor progression for early-stage Parkinson disease (PD) in the Phase IIb PADOVA trial ( …
-
Networknewsaudio Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks To Supercharge Reach, Impact Of GLP-1 Agonists With Proprietary Drug-Delivery Solution
20 Dec 2024 09:54 GMT
(MENAFN- Investor Brand Network)
Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent …
-
Silo Pharma Inc. (SILO) Spotlight: Ketamine
20 Dec 2024 09:39 GMT
(MENAFN- Investor Brand Network)
Ketamine shows promise in treating Alzheimer's Disease, Parkinson's disease as well as depression, suicide ideation and more
In 2021,
Silo Pharma (OTCQB: SILO)
entered into a
joint venture
with Zylö Therapeutics to …
-
‘Shrinking’s Latest Episode Is Already Foreshadowing This Major Development in Season 3
20 Dec 2024 08:12 GMT
Editor's Note: The following contains spoilers for 'Shrinking' Season 2, Episode 11.Season 2 of the Apple TV+ series Shrinking is coming to a close, airing its finale next week on Christmas Day. This season's storylines have centered on …
-
Vanderbilt researchers achieve milestone in Alzheimer's drug development
20 Dec 2024 01:49 GMT
Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a phase I single ascending dose clinical trial of …
-
Biomednewsbreaks - Clene Inc. (NASDAQ: CLNN) Secures $10 Million Debt Facility To Advance Neurodegenerative Disease Treatments
19 Dec 2024 20:02 GMT
(MENAFN- Investor Brand Network)
Clene (NASDAQ: CLNN)
has announced a $10 million debt facility with three affiliated entities, set to close by December 20, 2024. The 18-month secured, partially convertible note carries a 12% fixed interest rate, with an …
-
Roche's Parkinson's Disease Drug Misses Primary Endpoint
19 Dec 2024 17:28 GMT
Breaking News
Prasinezumab continues to be well tolerated and no new safety signals were observed.
12.19.24
Roche has announced results from its Phase IIb PADOVA study evaluating prasinezumab in patients with early-stage Parkinson’s disease. While the …
About
© 1995-2024